Regenxbio’s Duchenne Gene Therapy Shows Success in Trial, FDA Submission Next
Regenxbio announced positive results from its Duchenne muscular dystrophy gene therapy trial, achieving high levels of a critical muscle protein. The...
Xeber.world
Duchenne muscular dystrophy
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
Capricor Sues Nippon Shinyaku Over Delays and Pricing Flaw in Duchenne Drug Distribution Deal
Capricor Therapeutics has filed a lawsuit against Nippon Shinyaku and its U.S. subsidiary, NS Pharma, alleging they failed to execute marketing plans...
Capricor Therapeutics Takes Legal Action Against Partner Over Duchenne Therapy Launch Delays
Capricor Therapeutics has filed a lawsuit against its Japanese partner Nippon Shinyaku and subsidiary NS Pharma, alleging mismanagement in the launch...
Entrada’s Next-Gen Duchenne Drug Fails Early Trial, Sparking Competitive Concerns
Entrada Therapeutics’ next-generation exon-skipping drug for Duchenne muscular dystrophy underperformed in early trials, raising doubts about its comp...